PharmAthene, Inc.  

(Public, NYSEMKT:PIP)   Watch this stock  
Find more results for NYSEAMEX:PIP
2.38
+0.02 (0.85%)
Apr 29 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 2.28 - 2.39
52 week 1.20 - 2.49
Open 2.36
Vol / Avg. 256,383.00/334,523.00
Mkt cap 156.61M
P/E     -
Div/yield     -
EPS -0.05
Shares 65.25M
Beta 2.28
Inst. own 34%
May 5, 2016
Q1 2016 PharmAthene Inc Earnings Release (Estimated) Add to calendar
Mar 11, 2016
Q4 2015 PharmAthene Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin -97.78% -32.34%
Operating margin -74.26% -31.98%
EBITD margin - -6.21%
Return on average assets -24.37% -16.45%
Return on average equity -28.95% -19.70%
Employees 11 -
CDP Score - -

Address

1 Park Pl Ste 450
ANNAPOLIS, MD 21401-3481
United States - Map
+1-410-2692600 (Phone)
+1-410-2692601 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Pharmathene, Inc. (Pharmathene) is a biodefense company. The Company is focused on the development of medical counter measures against biological and chemical threats. The Company is involved in the development of two next generation anthrax vaccines. The Company's anthrax vaccines use recombinant protective antigen (rPA) manufacturing processes. The Company's product portfolio includes recombinant butyrylcholinesterase (rBChE) bioscavenger, which is used in prevention and treatment of nerve agent poisoning. The Company has developed a recombinant form of human butyrylcholinesterase for pre- and post-exposure therapy to patients with nerve agent attacks. Its rBChE bioscavenger acts with mechanism, which includes reversal of the acute toxicity associated with organophosphate poisoning agents used in chemical warfare (cholinergic crisis). Its development program also includes Valortim for monoclonal human antibody treatment.

Officers and directors

Mitchel B. Sayare Ph.D. Independent Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
John M. Gill President, Chief Executive Officer, Director
Age: 63
Bio & Compensation  - Reuters
Philip MacNeill Chief Financial Officer, Vice President, Treasurer, Secretary
Age: 62
Bio & Compensation  - Reuters
Eric I. Richman Director
Age: 54
Bio & Compensation  - Reuters
Jeffrey W. Runge M.D. Independent Director
Age: 59
Bio & Compensation  - Reuters
Derace L. Schaffer M.D. Independent Director
Age: 67
Bio & Compensation  - Reuters
Steven St. Peter M.D. Independent Director
Age: 48
Bio & Compensation  - Reuters